1. 1168PPhase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors. (23rd October 2018) Authors: Coward, J; Lemech, C; Meniawy, T; Dupont, C D; Gonzalez, A M; Lim, M; Savitsky, D; Carini, M; Hu, S; Shebanova, O; Dow, E; Ortuzar, W; Buell, J S; Stein, R B; Youssoufian, H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗